Trends in antidepressant use among children and adolescents
a Scandinavian drug utilization study

Wesselhoeft, R; Jensen, P B; Talati, A; Reutfors, J; Furu, K; Strandberg-Larsen, K; Damkier, P; Pottegård, A; Bliddal, M

Published in:
Acta Psychiatrica Scandinavica

DOI:
10.1111/acps.13116

Publication date:
2020

Document version:
Accepted manuscript

Citation for published version (APA):

Go to publication entry in University of Southern Denmark's Research Portal

Terms of use
This work is brought to you by the University of Southern Denmark. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to puresupport@bib.sdu.dk

Download date: 15. Sep. 2023
Trends in antidepressant use among children and adolescents: A Scandinavian drug utilization study

Antidepressant use in children and adolescents

Rikke Wesselhoeft1,2, Peter Bjødstrup Jensen1, Ardesheer Talati3, Johan Reutfors4, Kari Furu5, Katrine Strandberg-Larsen6, Per Damkier7,8, Anton Pottegård1, Mette Bliddal1,9

1) Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Denmark
2) Research Unit of Child and Adolescent Mental Health, Department of Clinical Research, University of Southern Denmark
3) Department of Psychiatry, Columbia University, Division of Epidemiology, New York State Psychiatric Institute
4) Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
5) Department of Chronic Diseases and Ageing and Centre for Fertility & Health, Norwegian Institute of Public Health, Norway
6) Section of Epidemiology, Department of Public Health, University of Copenhagen, Denmark
7) Department of Clinical Chemistry & Pharmacology, Odense University Hospital, Denmark
8) Department of Clinical Research, University of Southern Denmark, Denmark

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/acps.13116

This article is protected by copyright. All rights reserved
9) OPEN – Open Patient data Explorative Network, Department of Clinical Research, University of Southern Denmark and Odense University Hospital, Denmark

Correspondence
Rikke Wesselhoeft, Research Unit of Child and Adolescent Mental Health, Institute for Clinical Research, University of Southern Denmark, J. B. Winsløws Vej 16, Indgang 230, 5000 Odense C, rwesselhoeft@health.sdu.dk, +45-22358590

Acknowledgements
Rikke Wesselhoeft, Ardesheer Talati and Mette Bliddal are funded in part by NIH R01MH114967.

Conflicts of interest
Anton Pottegård reports participation in research projects funded by Alcon, Almirall, Astellas, Astra-Zeneca, Boehringer-Ingelheim, Novo Nordisk, Servier and LEO Pharma, all with funds paid to the institution where he was employed (no personal fees) and with no relation to the work reported in this paper. Johan Reutfors is employed at the Centre for Pharmacoepidemiology, Karolinska Institutet, which receives grants from several entities (pharmaceutical companies, regulatory authorities and contract research organisations) for performance of drug safety and drug utilization studies, with no relation to the work reported in this paper. Kari Furu, Ardesheer Talati, Rikke Wesselhoeft, Peter Bjøndstrup Jensen, Mette Bliddal, Katrine Strandberg-Larsen and Per Damkier report no conflicts of interest.
Abstract

Objective
To compare antidepressant utilization in individuals aged 5-19 years from the Scandinavian countries.

Methods
A population-based drug utilization study using publicly available data of antidepressant use from Denmark, Norway, and Sweden.

Results
In the study period from 2007 to 2017, the proportion of antidepressant users increased markedly in Sweden (9.3-18.0/1000) compared to Norway (5.1-7.6/1,000) and Denmark (9.3-7.5/1,000). In 2017, the cumulated defined daily doses (DDD) of selective serotonin reuptake inhibitors was 5,611/1,000 inhabitants in Sweden, 2,709/1,000 in Denmark, and 1,848/1,000 in Norway. The use of ‘other antidepressants’ (ATC code N06AX) also increased in Sweden with a higher DDD in 2017 (497/1,000) compared to Denmark (225/1,000) and Norway (170/1,000). The use of tricyclic antidepressants was generally low in 2017 with DDDs ranging between 30-42 per 1,000. The proportion of antidepressant users was highest among 15-19 year-old individuals. Girls were more likely to receive treatment than boys, and the treated female/male ratios per 1,000 were similar in Sweden (2.39), Denmark (2.44), and Norway (2.63).

Conclusion
Even in highly comparable health-care systems like the Scandinavian countries’, variation in antidepressant use is considerable. Swedish children and adolescents have a markedly higher and still increasing use of antidepressants compared to Danish and Norwegian peers.

Keywords (3-5)
Drug utilization, depression, anxiety, obsessive compulsive disorder, SSRI
**Significant outcomes**

- In the year 2017, Swedish children and adolescents were more than twice as likely to fill an antidepressant prescription compared to Danish and Norwegian peers
- Girls were more than twice as likely to be treated with antidepressants compared to boys in all three countries

**Limitations**

- The analyses were based on filled prescriptions as proxies for antidepressant use
- The study data does not include information about indications for the prescribed drugs and questions regarding the appropriateness of antidepressant use remains unanswered
Introduction

The efficacy and safety of antidepressant use in children and adolescents has been subject to controversy and debate (1, 2). This culminated in the first decade of the 2000s, when regulatory authorities provided warnings based on reports of increased suicide-related behavior due to use of selective serotonin reuptake inhibitors (SSRIs) in youth (1, 3). The U.S. Food and Drug Administration (FDA) issued a ‘black box’ label warning in 2004 on the use of SSRIs in children and adolescents (4), which in 2007 was expanded to include young adults up to age 25 years (5). Accordingly, the European Medicines Agency recommended ‘strong warnings across the whole of the European Union to doctors and patients about these risks’ regarding antidepressant use for children and adolescents in 2005 (6).

Selective serotonin reuptake inhibitors (SSRIs) are the only antidepressants approved by the European Medicines Agency for treatment of children in Europe, with specific SSRIs holding licensed indications for childhood depressive episodes and obsessive compulsive disorder (OCD). Tricyclic antidepressants (TCAs) are not documented effective for treatment of depression (7) or anxiety disorders (8) in children or adolescents, but are nevertheless sometimes considered second line treatment (9). Some TCAs hold a licensed indication for nocturnal enuresis even though not considered first line treatment (10).

Noradrenergic and specific serotonergic antidepressants (NaSSA) are approved for treatment in adults (11) but not in children and adolescents. Similarly, serotonin-norepinephrine reuptake inhibitors (SNRI) are not documented effective for treatment of depression in children or adolescents (12). However, they seem effective for treatment of anxiety disorders (13-15) and duloxetine has been approved for treatment of pediatric generalized anxiety disorders in the US, but not in Europe.

The most recent studies of antidepressant use in children and adolescents show increasing prevalence (16-19) and incidence (18, 20, 21) rates. However, the studies are characterized by limited examination of specific drugs, only one reporting of utilization after 2013 (22), and only one study comparing antidepressant utilization between countries (16). Finally, this is the first study to compare antidepressant utilization among Scandinavian children and adolescents. The Scandinavian countries are characterized by high living standards and a fairly equal income distribution (23), and the Scandinavian health care systems are quite similar and almost exclusively publicly funded through taxation (24).

Aims of the Study
We aimed to compare patterns and trends of antidepressant utilization (filled prescriptions) in the last decade among individuals aged 5-19 years in Denmark, Norway, and Sweden.

Material and methods

Study populations

This is a population-based descriptive drug utilization study including three nation-wide populations using publicly available data for the study period of January 1\textsuperscript{st} 2007 - December 31\textsuperscript{st} 2017. The study population consisted of all individuals aged 5-19 years from Denmark (1,012,855 in 2017), Norway (959,237 in 2017), and Sweden (1,693,565 in 2017) (www.nordicstatistics.org). The number of individuals aged 5-19 years in each country and year was used as the denominator when calculating the proportion of antidepressant users. Children under the age of 5 years were excluded due to negligible use of antidepressants. The upper age limit of 19 years was chosen in accordance with the World Health Organization (WHO) definition of adolescence (25).

Data sources

Data was retrieved from the public authorities’ freely accessible websites that provide validated information on filled medication prescriptions; www.medstat.dk, www.socialstyrelsen.se, www.norpd.no. The prescription databases of the Scandinavian countries hold valid information on drug groups and the period prevalence of a given drug per 1,000 persons per year within a given age range and sex (26).

Variables

Filled prescriptions of antidepressants were used as proxies for actual consumption of drugs. Drugs were defined according to the WHO Anatomic Therapeutic Chemical (ATC) classification system (27), and the study included prescriptions of drugs with any ATC code of N06A* (antidepressants) (* referring to inclusion of all drugs in this category). The antidepressants were further divided into three drug groups: 1) SSRIs (ATC code N06AB*), 2) TCAs (ATC code N06AA* (Non-selective monoamine reuptake inhibitors)), and 3) 'other antidepressants' (ATC codes N06AX*) including serotonin-norepinephrine reuptake inhibitors, noradrenergic and specific serotonergic antidepressants, melatonin agonists, serotonin agonists and antagonists, and aminoketone and noradrenaline reuptake inhibitors. Due to the hierarchical structure of ATC levels, any reporting of
total antidepressant use (N06A*) also contained use of monoamine oxidase inhibitors (N06AF and N06AG). The use of these drugs was however extremely rare. The quantity dispensed for each drug prescription is expressed by the defined daily dose (DDD) measure, which is defined as ‘the assumed average maintenance dose per day for a drug used for its main indication in adults’ (27). Specifications of included antidepressant drugs with and without licensed indication for use in children and adolescents (<18 years) are shown in Table 1.

Table 1 about here

Statistical analyses

In order to show trends of antidepressant use, we obtained the annual number of 5-19-year-olds per 1,000 individuals (prevalence) in each country, who filled at least one prescription for antidepressants (by drug group and total) in the years 2007-2017. We illustrated the annual number of antidepressant users (per 1,000) in 2017, by sex, age group, and country. Finally, the total cumulated yearly amount of DDDs of the most frequently used antidepressants in 2007-2017 among 5-19-year-olds (per 1,000 individuals) was determined. This was analyzed by country, drug group, drug, year and age group.

All statistical analyses were performed using STATA Release 15.0 (StataCorp, College Station, TX, USA) and R (28), including the tidyverse packages (29).

Data availability statement

The data that support the findings of this study are openly available in Zenondo.org at [https://zenodo.org/deposit/3366068]. The data were derived from the following resources in the public domain:

Drug statistics data:
https://sdb.socialstyrelsen.se/if_lak/val.aspx (download date: 2018.10.24)
http://www.norpd.no/ (download date: 2018.10.24)
http://www.medstat.dk/ (download date: 2018.01.10)

Census data:
http://www.statistikdatabasen.scb.se (download date: 2018.10.24)
https://www.ssb.no/ (download date: 2018.10.24)
https://statistikbanken.dk (download date: 2018.01.10)
Ethics
The data are publicly accessible in the three countries and approval from any ethical committee or data protection agency is therefore not required.

Results
Throughout the study period, the number of young antidepressant users increased markedly in Sweden (from 9.3 to 18/1000), whereas it increased slightly in Norway (from 5.1 to 7.6/1,000) and decreased in Denmark (from 9.3 to 7.5/1,000) after a peak in 2010 (13/1,000) (Figure 1, Supplement Table 1). Thus, Swedish children and adolescents were more than twice as likely to fill an antidepressant prescription in 2017 (1.8%) compared to Danish (0.75%) and Norwegian (0.76%) peers. The increase in Swedish use was accounted for by SSRIs and ‘other antidepressants’, whereas the number of TCA users in 2017 was larger in Norway (0.9/1,000) than in Denmark (0.5/1,000) and Sweden (0.5/1,000).

The extensive antidepressant treatment of Swedish individuals compared to Danish and Norwegian peers applied across age groups (Figure 2, Supplement Table 2). It was however most pronounced for 5-9-year-olds, who were four times more likely to receive treatment in Sweden (0.69/1,000) than Danish (0.17/1,000) and Norwegian (0.18/1,000) children, although the overall use was low. As expected, antidepressant use increased in late adolescence (15-19 years), but the age-related increase (from 10-14 years) was almost twice as high in Norway for both males (Norway, 6.4, Denmark 3.9, Sweden 3.3) and females (Norway 17, Denmark 8.9, Sweden 7.2).

Female antidepressant users (per 1,000) were more than twice as frequent as male users (Denmark 10 vs. 4.8, Norway 11 vs. 4.6, Sweden 24 vs. 12) (Figure 2). The preponderance of female antidepressant users per 1,000 was markedly higher in the age group 15-19 years (Sweden 68 vs. 28, Denmark 27 vs. 11, Norway 30 vs. 12).
SSRIs were the most commonly used antidepressants in all three countries, with a total cumulated DDD of 5,611/1,000 in Sweden, 2,709/1,000 in Denmark and 1,848/1,000 in Norway in 2017 (Figure 3, Supplement Table 3). Sertraline was most frequently used in 2017, followed by fluoxetine and in Norway by escitalopram to the same extent. The total DDD of ‘other antidepressants’ in 2017 was 497/1,000 in Sweden, 225/1,000 in Denmark, and 170/1,000 in Norway. Venlafaxine and mirtazapine were most commonly used and there was a trend of increasing use of various ‘other antidepressants’ in Sweden. The total use of TCAs was generally low, with DDD of 30/1,000 in Sweden, 38/1,000 in Denmark, and 42/1,000 in Norway.

Sertraline and fluoxetine were also the most commonly used SSRIs, when looking at age groups separately in each country (Supplement Figure 1). ‘Other antidepressants’ were rarely used for 5-14-year-olds but a general increasing trend in use was observed for all age groups in Sweden (Supplement Figure 2). TCAs were rarely used under the age of ten (Supplement Figure 3). Amitriptyline and imipramine were the most commonly used TCAs for 5-14-year-olds. Amitriptyline was most frequently used in 15-19-year-olds with some use of clomipramine in Sweden and nortriptyline in Denmark.

Discussion
This study demonstrates that trends of antidepressant utilization in children and adolescents differed markedly between the Scandinavian countries from 2007 through 2017. There was an increasing use of SSRIs and ‘other antidepressants’ in Sweden, while Norway and Denmark appeared to move towards a stable and lower use. In 2017, Swedish children and adolescents were more than twice as likely to fill an antidepressant prescription (1.8%) compared to Danish (0.75%) and Norwegian (0.76%) peers. Hence, two out of three Scandinavian countries did not display an increasing trend in antidepressant use as opposed to earlier findings in young Scandinavian samples (17-20) and samples from other countries (16, 21). However, the study periods of those studies ended no later than 2013. A French study examining antidepressant use until 2016 showed a decrease in use at age 6-11 years and just a minor increase at age 12-17 years (22), similar to our findings.

The marked drop in antidepressant use in Denmark from 2010 could reflect a delayed dissemination of the FDA black box warning leading to a reluctance in prescription of antidepressants for children and adolescents. A large US study showed that there were significant reductions of antidepressant
utilization rates within two years after the FDA warning and that these continously remained lower than the rates of 2004 (30). The drop could however also illustrate a ‘spilover effect’ because studies showed that the antidepressant regulatory warnings actually led to a reduction in the numbers of youths (31-33) and adults (33, 34) diagnosed with depression and treated for the disorder. Still, this does not explain the trend of an increasing use in Sweden, where the licensed indications for antidepressants are similar to those of Denmark and Norway. Our results showed that Swedish children and adolescents were two-four times more likely to receive treatment with SSRIs and ‘other antidepressants’ than their Norwegian and Danish peers in 2017, depending on age group.

The use of TCAs was limited and stable throughout the last decade except that there was an increasing trend in Norway. Amitriptylin (and in Denmark also imipramin) holds a licensed indication for nocturnal enuresis in all three countries, which probably explains the main part of use (10). Amitriptyline and imipramine are occasionally used for treatment of pediatric chronic pain (35, 36), and amitriptyline also for migraine prevention (37, 38) and pain-related functional gastrointestinal disorders (39). However, neither drug holds licensed indications for these purposes in children and adolescents. Clomipramine and nortriptyline were also used for the age group of 15-19-year-olds, likely due to second line treatment.

The Global Burden of Disease study provides online data (https://gbd2016.healthdata.org/gbd-search/) showing that the Scandinavian countries have comparable frequencies of depression and anxiety disorders for individuals aged 10-19 years. However, the Swedish prevalence rates of childhood depressive episodes seem to be somewhat higher than those of Denmark and Norway, a finding supported by studies examining the three countries separately (40-42). The prevalence of anxiety disorders in children and adolescents on the other hand, appears to be slightly higher in Norway compared to Denmark and Sweden, whereas similar prevalence proportions (approximately 5%) were reported in a Danish (43) and Norwegian (44) study. A study comparing OCD prevalence rates between countries (not including Norway) showed that the age-specific prevalence rates were markedly lower in Sweden compared to Denmark (45). Hence, there is a lack of studies that compare the frequencies of childhood depression and anxiety disorders between the Scandinavian countries using comparable outcome measures and age groups. Variation in disease frequency could be a plausible explanation for the different patterns of antidepressant use in between Scandinavian countries. It is also possible that access to National clinical guidelines may influence prescription patterns. Currently, Sweden is the only Scandinavian country where up-to-date National clinical guidelines are available for the treatment of all three conditions (depression, anxiety and OCD) that are most commonly associated with antidepressant use in children and adolescents (46).
The Scandinavian countries have given rise to the term ‘the Scandinavian welfare model’ and provide very comparable health care systems (24) although minor differences exist (23). The licensed indications for antidepressant use for children and adolescents are also similar in the three countries (as illustrated in our Table 1). Still, Scandinavian differences in treatment patterns have previously been observed regarding attention deficit hyperactivity disorder (47). A comparison of 28 EU countries showed that Sweden had the highest availability of child and adolescent psychiatrists per 100,000 young people (23.4) compared to all countries, including Denmark (10.3) (48). The rates of Scandinavian children diagnosed with depression and OCD diagnoses seem to be rising (42, 45, 49). Our findings could reflect that Swedish children and adolescents are treated more extensively pharmacologically for these disorders due to higher availability of mental health services (48).

The most significant strengths of our study are the use of three nationwide study populations and validated exposure data sets that eliminate selection and recall bias. The analyses of our study were based on filled prescriptions as proxies for antidepressant use. Although filled prescriptions are considered superior to information collected from medical records or questionnaires (26) and are more indicative of use than prescriptions alone (50), they may not reflect consumption exactly. However, the agreement between filled prescription data and self-reported antidepressant medication is reported to be good in a large population-based study (51). Furthermore, our study holds the limitations that the data sources used did not provide information on indications for antidepressant use nor did they allow us to differentiate between incident and prevalent antidepressant users. Finally, drugs dispensed in hospital were not included in the databases.

Concluding remarks

In this comprehensive drug utilization study, we found that Swedish children and adolescents were more than twice as likely to receive treatment with an SSRI than their Danish and Norwegian peers. Most distinctly, Swedish 5-9-year-olds had a fourfold likelihood of receiving antidepressant treatment compared to other Scandinavian children. The health care systems in the Scandinavian countries are considered quite comparable. However, the availability of child and adolescent psychiatrists is markedly higher in Sweden compared to other EU countries and the access to national clinical guidelines for treatment of depression and anxiety disorders differ between the three countries. The Global Burden of Disease study provides data indicating that the prevalence rates of depression and anxiety disorders are comparable in the Scandinavian countries but the literature is sparse. We
recommend that future studies examine these health care differences further in order to find possible explanations for the variation of antidepressant use in Scandinavian children and adolescents.

References


This article is protected by copyright. All rights reserved


Table 1. Licensed indication for use of antidepressants in children and adolescents (younger than 18 years) in Denmark, Norway, and Sweden.

**Abbreviations:** TCA (tricyclic antidepressants), SSRI (selective serotonin reuptake inhibitors), OCD (obsessive compulsive disorder), DDD (defined daily dose, defined as the assumed average maintenance dose per day for a drug used for its main indication in adults).

* Moderate to severe depression if no remission after 4-6 weeks of psychological treatment.

**Figure 1.** Number of annual antidepressant users (per 1,000) aged 5-19 years by country (*note: variation in y-axis*).

**Abbreviations:** ATC (Anatomical Therapeutic Chemical).

**Figure 2.** Number of antidepressant users (per 1,000) by sex and age group in Denmark, Norway, and Sweden in 2017.

**Figure 3.** Cumulated annual defined daily dose (DDD) of antidepressants by drug group per 1,000 inhabitants (aged 5-19 years) in Denmark, Norway, and Sweden (*note variation in y-axis*).
**Supplement Figure 1.** Cumulated annual defined daily dose (DDD) of selective serotonin reuptake inhibitors (SSRI) (ATC code N06AB) per 1,000 inhabitants (by country, age group and drug) in Denmark, Norway, and Sweden (note variation in y-axes).

**Supplement Figure 2.** Cumulated annual defined daily dose (DDD) of ‘other antidepressants’ (ATC code N06AX) per 1,000 inhabitants (by country, age group and drug) in Denmark, Norway, and Sweden (note variation in y-axes).

**Supplement Figure 3.** Cumulated annual defined daily dose (DDD) of tricyclic antidepressants (TCA) (ATC code N06AA) per 1,000 inhabitants (by country, age group and drug) in Denmark, Norway, and Sweden (note variation in y-axes).

**Supplement Table 2.** Number of antidepressant users (per 1,000) aged 5-19 years by country, year and drug group.

Abbreviations: DK (Denmark), NO (Norway), SE (Sweden), AD (all antidepressants), TCA (tricyclic antidepressants), SSRI (selective serotonin reuptake inhibitors), OD (other antidepressants).

**Supplement Table 2.** Number of antidepressant users (per 1,000) by country, sex and age group in 2017.

Abbreviations: M (male), F (female).

**Supplement Table 3.** Defined daily dose (DDD) of antidepressants by country, year and drug per 1,000 inhabitants (aged 5-19 years).

Abbreviations: DK (Denmark), NO (Norway), SE (Sweden).
<table>
<thead>
<tr>
<th>Drug group</th>
<th>ATC Code</th>
<th>Drug</th>
<th>DDD (mg)</th>
<th>Denmark Year of licensed indication</th>
<th>Norway Year of licensed indication</th>
<th>Sweden Year of licensed indication</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TCA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N06AA</td>
<td>Imipramin</td>
<td>100</td>
<td>Before 1995 (nocturnal enuresis ≥6 years)</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>N06AA</td>
<td>Imipraminoxid</td>
<td>100</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>N06AA</td>
<td>Clomipramin</td>
<td>100</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>N06AA</td>
<td>Amitriptylin</td>
<td>75</td>
<td>2017 (nocturnal enuresis ≥6 years)</td>
<td>1976 (nocturnal enuresis ≥6 years)</td>
<td>2017 (nocturnal enuresis ≥6 years)</td>
</tr>
<tr>
<td></td>
<td>N06AA</td>
<td>Nortriptylin</td>
<td>75</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td><strong>SSRI</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N06AB</td>
<td>Fluoxetine</td>
<td>20</td>
<td>2006 (Depression* ≥ 8 years)</td>
<td>2008 (Depression* ≥8 years)</td>
<td>2006 (Depression* ≥ 8 years)</td>
</tr>
<tr>
<td></td>
<td>N06AB</td>
<td>Citalopram</td>
<td>20</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>N06AB</td>
<td>Paroxetine</td>
<td>20</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>N06AB</td>
<td>Sertraline</td>
<td>50</td>
<td>2001 (OCD ≥ 6 years)</td>
<td>2000 (OCD ≥ 6 years)</td>
<td>1999 (OCD ≥ 6 years)</td>
</tr>
<tr>
<td></td>
<td>N06AB</td>
<td>Fluvoxamine</td>
<td>100</td>
<td>2006 (OCD ≥ 8 years)</td>
<td>2002 (OCD &gt; 8 years)</td>
<td>2002 (OCD &gt; 8 years)</td>
</tr>
<tr>
<td></td>
<td>N06AB</td>
<td>Escitalopram</td>
<td>10</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td><strong>Other antidepressants</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N06AX</td>
<td>Venlafaxine</td>
<td>100</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>N06AX</td>
<td>Duloxetine</td>
<td>60</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>N06AX</td>
<td>Mirtazapine</td>
<td>30</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>N06AX</td>
<td>Mianserin</td>
<td>60</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>N06AX</td>
<td>Bupropion</td>
<td>300</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This article is protected by copyright. All rights reserved
<table>
<thead>
<tr>
<th>Code</th>
<th>Name</th>
<th>Dose</th>
<th>Range</th>
<th>Side effects</th>
<th>Other adverse effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>N06AX18</td>
<td>Reboxetine</td>
<td>8</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>N06AX26</td>
<td>Vortioxetine</td>
<td>10</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>N06AX22</td>
<td>Agomelatine</td>
<td>25</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>N06AX06</td>
<td>Nefazodone</td>
<td>400</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>N06AF01</td>
<td>Isocarboxazid</td>
<td>15</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>N06AG2</td>
<td>Moclobemid</td>
<td>300</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

Table 1. Licensed indication for use of antidepressants in children and adolescents (younger than 18 years) in Denmark, Norway and Sweden.

**Abbreviations:** TCA (tricyclic antidepressants), SSRI (selective serotonin reuptake inhibitors), OCD (obsessive compulsive disorder), DDD (defined daily dose, defined as the assumed average maintenance dose per day for a drug used for its main indication in adults).

* Moderate to severe depression if no remission after 4-6 weeks of psychological treatment.
Figure 1. Number of annual antidepressant users (per 1,000) aged 5-19 years by country (note: variation in y-axes).

Abbreviations: ATC (Anatomical Therapeutic Chemical).
**Figure 2.** Number of antidepressant users (per 1,000) by sex and age group in Denmark, Norway, and Sweden in 2017.
Figure 3. Cumulated annual defined daily dose (DDD) of antidepressants by drug group per 1,000 inhabitants (aged 5-19 years) in Denmark, Norway, and Sweden (note variation in y-axes).